JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

6.99 -2.51

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.92

Max

7.28

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

102.429

121.746

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+60.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-737M

1.1B

Iepriekšējā atvēršanas cena

9.5

Iepriekšējā slēgšanas cena

6.99

Ziņu noskaņojums

By Acuity

50%

50%

149 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. febr. 23:26 UTC

Galvenie tirgus virzītāji

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

2026. g. 10. febr. 22:31 UTC

Peļņas

Correction to America Movil 4Q Profit Article

2026. g. 10. febr. 22:22 UTC

Peļņas

America Movil 4Q Profit Jumps on Lower Financial Costs

2026. g. 10. febr. 23:51 UTC

Tirgus saruna
Peļņas

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

2026. g. 10. febr. 23:42 UTC

Tirgus saruna

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

2026. g. 10. febr. 23:40 UTC

Tirgus saruna
Peļņas

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

2026. g. 10. febr. 23:21 UTC

Tirgus saruna

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

2026. g. 10. febr. 23:21 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 10. febr. 22:17 UTC

Tirgus saruna

Australia's One Nation Now Commands Working Class Vote -- Market Talk

2026. g. 10. febr. 22:15 UTC

Peļņas

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

2026. g. 10. febr. 22:10 UTC

Peļņas

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

2026. g. 10. febr. 22:10 UTC

Peļņas

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

2026. g. 10. febr. 22:09 UTC

Peļņas

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

2026. g. 10. febr. 22:09 UTC

Peļņas

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

2026. g. 10. febr. 22:01 UTC

Peļņas

Intact Financial 4Q EPS C$5.24 >IFC.T

2026. g. 10. febr. 21:54 UTC

Peļņas

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

2026. g. 10. febr. 21:53 UTC

Peļņas

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

2026. g. 10. febr. 21:51 UTC

Peļņas

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

2026. g. 10. febr. 21:51 UTC

Peļņas

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026. g. 10. febr. 21:51 UTC

Peļņas

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

2026. g. 10. febr. 21:51 UTC

Peļņas

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

2026. g. 10. febr. 21:51 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

2026. g. 10. febr. 21:50 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

2026. g. 10. febr. 21:50 UTC

Peļņas

James Hardie Industries 3Q EPS 12c >JHX

2026. g. 10. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 10. febr. 21:50 UTC

Peļņas

James Hardie Industries 3Q Adj EPS 24c >JHX

2026. g. 10. febr. 21:49 UTC

Peļņas

James Hardie Industries 3Q Sales $1.24B >JHX

2026. g. 10. febr. 21:49 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

2026. g. 10. febr. 21:48 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

2026. g. 10. febr. 21:47 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

60.03% augšup

Prognoze 12 mēnešiem

Vidējais 11.57 USD  60.03%

Augstākais 13 USD

Zemākais 9 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

6

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

149 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat